Advance system testing: Vaccine benefit studies using multi-country electronic health data – The example of pertussis vaccination
- Tin Tin Htar, M. (Myint)
- Ridder, M.A.J. (Maria) de
- Braeye, T. (Toon)
- Correa, A. (Ana)
- McGee, C. (Chris)
- Lusignan, S. (Simon) de
- Duarte-Salles, T. (Talita)
- Huerta Alvarez, C. (C.)
- Martín-Merino, E. (Elisa)
- Tramontan, L. (Lara)
- Danieli, G. (Giorgia)
- Picelli, G. (Gino)
- Maas, N.A.T. (Nicoline) van der
- Berencsi, K. (Klára)
- Arnheim-Dahlström, L. (Lisen)
- Heininger, U. (Ulrich)
- Emborg, H.-D. (Hanne-Dorthe)
- Weibel, D.M. (Daniel)
- Bollaerts, K. (Kaatje)
- Sturkenboom, M.C.J.M. (Miriam)
DOIAbstract
The Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE), a public-private consortium, implemented and tested a distributed network system for the generation of evidence on the benefits-risks of marketed vaccines in Europe. We tested the system by estimating the incidence rate (IR) of pertussis and pertussis-related complications in children vaccinated with acellular (aP) and whole-cell (wP) pertussis vaccine. Data from seven electronic databases from four countries (Denmark: AUH and SSI, Spain: SIDIAP and BIFAP, UK: THIN and RCGP RSC and Italy: Pedianet) were included in a retrospective cohort analysis. Exposure was defined as any pertussis vaccination (aP or wP). The follow-up time started 14 days after the fi...
Add to ORKG